574 followers
MA: Patients with MDD who received pharmacogenomic-guided antidepressant prescribing were 41% to 78% more likely to achieve remission and 20% to 49% more likely to respond to ADs than patients receiving treatment-as-usual (MD=3.29; 0.60-5.98; I²=20%) https